Barclays
IBIO icon

Barclays’s iBio IBIO Stock Holding History

Barclays’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$4 – 5224
2025
Q4 		$4 Buy
+2
New +$3 ﹤0.01% 5169
2025
Q2 		– Sell
-82
Closed -$330 – 5394
2025
Q1 		$330 Buy
+82
New +$319 ﹤0.01% 5106
2022
Q2 		– Sell
-70
Closed -$16K – 5136
2022
Q1 		$16K Sell
70
-455
-87% -$95.2K ﹤0.01% 4501
2021
Q4 		$144K Buy
525
+348
+197% +$133K ﹤0.01% 3651
2021
Q3 		$93K Sell
177
-26
-13% -$16.2K ﹤0.01% 3933
2021
Q2 		$153K Sell
203
-303
-60% -$221K ﹤0.01% 3662
2021
Q1 		$389K Buy
506
+390
+336% +$340K ﹤0.01% 3335
2020
Q4 		$61K Hold
116
– – ﹤0.01% 4329
2020
Q3 		$118K Buy
116
+24
+26% +$34.8K ﹤0.01% 4157
2020
Q2 		$103K Buy
+92
New +$60.2K ﹤0.01% 4494
2020
Q1 		– Sell
-60
Closed -$7K – 6276
2019
Q4 		$7K Buy
+60
New +$8.13K ﹤0.01% 6138

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Barclays's IBIO Position: Q1 2026 in Review

Barclays sold out of iBio (IBIO) in Q1 2026, closing a stake of 2 shares — an estimated $4 sold.

Barclays first reported a position in IBIO in Q4 2019 and held it in 11 quarters. The position peaked at $389K in Q1 2021. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Barclays reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 2 iBio shares in Q1 2026, an estimated $4.
  • Barclays first reported a position in iBio in Q4 2019 and held it in 11 quarters.
  • Barclays's iBio position peaked at $389K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.